Dear TechNet members, We would like to know the appropriate age for Td vaccine and whether what we are practising is right. As per the manufacturer’s leaflet (Serum Institute of India), Td vaccine is for primary vaccination and revaccination of children older than 7 years. However, in Bhutan, we are giving at 6 years also.  Our immunization schedule for DTP containing  and Td vaccine is as follows: DTP-HepB-Hib (Pentavalent) at 6, 10 and 14 weeks. DTP at 24 months Td at 6 and 12 years Td at pregnancy Best regards, Chandralal

1. How many doses (maximum) of tetanus doses is required in a ilfe time? 2. Is there a booster dose? 3. How many doses of tetanus is required after a cut injury?  With regards  Dr. Dhrupthob Sonam

The SAGE October 2016 meeting report has been published in the WHO Weekly Epidemiological Record. SAGE reviewed relevant data and evidence, advised and made recommendations on various complex and critical issues including: Global Vaccine Action Plan: 2016 mid-term review of progress and recommendations Maternal and neonatal tetanus elimination (MNTE) and broader tetanus prevention Measles and rubella elimination Hepatitis B vaccination Schedules and strategies for human papillomavirus (HPV) immunization Yellow fever Polio eradication The meeting report can be downloaded at http://apps.who.int/iris/bitstream/10665/251810/1/WER9148.pdf?ua=1

The latest WHO and UNICEF estimates of immunization coverage show that 86% of the world’s children received the required 3 doses of diphtheria-tetanus-pertussis containing vaccines (DTP3) in 2015, a coverage level that has been sustained above 85% since 2010.As a result, the number of children who did not receive routine vaccinations has dropped to an estimated 19.4 million, down from 33.8 million in 2000.However, this progress falls short of global immunization targets (90% or more DTP3 vaccination coverage at the national level, and 80% or more in all districts in all countries) by 2015.
Read the full storyhere, and have a look at thisanimated map to see how global DTP3 coveragechanges from 2000 to 2015.
A short presentation with some highlights is posted here.
Want more detail? All the raw data can be foundhere.

WHO and UNICEF have jointly prepared an information bulletin which addresses varied implications of different types of vaccine vial monitors (VVMs), notably VVM category type 7 (VVM7) and VVM category type 14 (VVM14), on vaccines such as the Inactivated Polio Vaccine (IPV) and the fully-liquid Diphtheria-Tetanus- whole cell Pertussis-Hepatitis B-Haemophilus influenzae type b (DTP-HepB-Hib, commonly referred to as pentavalent). The note is directed to countries that are currently supplied by UNICEF Supply Division with these specific presentations of vaccine. The information is intended for WHO/UNICEF staff, as well as EPI managers or other partner agencies which support immunization programmes.

Both the english and french versions are attached here.

Here are some of the latest immunization data available on the WHO website:

Global Immunization Data

Summary: Global immunization coverage in 2012

Immunization currently averts an estimated two to three million deaths every year in all age groups from diphtheria, tetanus, pertussis (whooping cough), and measles.

In 2012, an estimated 83% (111 million) of infants worldwide were vaccinated with three doses of diphtheria-tetanus-pertussis (DTP3) vaccine. Three regions ? the Americas, Europe and Western Pacific ? maintained over 90% DTP3 immunization coverage, the Western Pacific reaching 97%.

Number of countries reaching 80% or more immunization coverage with DTP3 vaccine in 2012: 165 countries compared to 164 in 2011.

Number of countries reaching over 90% or more immunization coverage with DTP3 vaccine in 2012: 131 countries compared to 128 in 2011.

Increasing uptake of new and underused vaccines
Hepatitis B vaccine for infants was introduced nationwide in 181 countries by the end of 2012. Global coverage with three doses of hepatitis B vaccine is estimated at 79% and is as high as 91% in the Western Pacific and the Americas. Coverage in the South-East Asia Region reached 72% in 2012 up from 56% in 2011.

Haemophilus influenzae type B (Hib) vaccine was introduced in 184 countries by the end of 2012 (including in parts of Belarus, India, Maldives and Nigeria), up from 177 countries in 2011. Global coverage with three doses of Hib vaccine is estimated at 45% in 2012, reaching 91% in the Americas, but only 11% and 14% in the South-East Asia Region and in the Western Pacific Region, respectively.

Rubella vaccine was introduced nationwide in 132 countries by the end of 2012, up from 85countries in 1996. There has been remarkable progress towards the elimination of rubella and congenital rubella syndrome in the Americas with a reduction of99.99% of confirmed cases between 1998 and 2012.

Mumps vaccine was introduced nationwide in 120 countries by the end of 2012.

Yellow fever vaccine was introduced in routine infant immunization programmes in 36 countries and territories out of the 48 at risk for yellow fever in Africa and the Americas.

Maternal and neonatal tetanus (MNT): One hundred and three countries provide Tetanus Toxoid-containing vaccine to prevent against maternal and neonatal tetanus (MNT). In these countries, the estimate for the protection of newborns at birth from tetanus that is derived from vaccination coverage
with at least two doses of Tetanus Toxoid vaccine or Tetanus-diphtheria Toxoid vaccine was estimated at 81% in 2012. As of December 2012, maternal and neonatal tetanus persist as a public health problems in 30 countries, mainly in Africa and Asia.

You can access more data here.

The WHO page: http://www.who.int/immunization/monitoring_surveillance/en/